Lava Therapeutics Bv Stock Price, News & Analysis

LAVA Therapeutics (Nasdaq: LVTX) announced a virtual symposium titled Emerging cancer therapies leveraging gamma-delta effector T cells scheduled for Nov. 29, 2021. Co-organized with The Antibody Society, the event features leading experts discussing advancements in cancer therapeutics using gamma-delta T cells. Notable speakers include Prof. Hans van der Vliet and Prof. James Allison. The symposium aims to explore the therapeutic potential of these T cells in oncology.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced the expansion of its management team with three key appointments. Jessica Truscello joins as Vice President of Clinical Operations, bringing over 20 years of oncology expertise. Sumeet Ambarkhane, M.D. becomes the Executive Medical Director, leveraging his 17 years in oncology and hemato-oncology. Wouter van Hunnik is appointed Vice President of Human Resources, with over 15 years of HR leadership experience. These additions aim to enhance LAVA's capabilities as it transitions to a clinical-stage organization focused on developing bispecific gamma delta T cell engagers for cancer treatment.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will participate in a virtual fireside chat at the 12th Annual Jefferies London Healthcare Conference from Nov. 16-19, 2021. The chat will be available from 3:00 a.m. ET on Nov. 18 until 12:00 p.m. ET on Nov. 19. LAVA's leadership will also engage in one-on-one investor meetings during the event. Attendees can register for the conference and access the recording of the chat on LAVA's investor relations website.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that Paul W.H.I. Parren, Ph.D., its EVP and Head of R&D, will present data on bispecific gamma delta T cell engagers from their proprietary Gammabody™ platform at three upcoming scientific conferences in November 2021. The platform aims to revolutionize cancer treatment by combining effective tumor cell killing with low toxicity risks. Dr. Parren will chair sessions and participate in key discussions, including one on Nov. 3 at the Annual PEGS Europe Summit and another on Nov. 9 during the European Antibody Congress.

LAVA Therapeutics (Nasdaq: LVTX) announced that the FDA granted orphan drug designation for LAVA-051, a bispecific antibody targeting chronic lymphocytic leukemia (CLL). The designation will facilitate communication with the FDA and provide incentives for development, such as tax credits and potential market exclusivity. LAVA-051 is currently in a Phase 1/2a clinical trial for relapsed or refractory CLL, multiple myeloma, and acute myeloid leukemia, with preliminary data expected in 2022.

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, announced that Hans van der Vliet, M.D., Ph.D., their chief scientific officer, will present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The presentation will highlight their bispecific gamma delta T cell engagers, focusing on V9V2 T cells and preclinical data from the LAVA-051 program. The session is set for October 8, 2021, from 12:05 to 1:55 p.m. ET.

LAVA Therapeutics (Nasdaq: LVTX) reported progress in its clinical trials and financial results for Q2 2021. The Phase 1/2a trial of LAVA-051 for hematological malignancies has initiated dosing, with results expected in early 2022. The CTA and IND for LAVA-1207 in metastatic castration-resistant prostate cancer have been accepted, with enrollment beginning later this year. The company holds a cash balance of €128.4 million, expected to fund operations into late 2023. Revenue from its collaboration with Janssen increased, but net losses grew to €5.8 million for Q2.

LAVA Therapeutics N.V. (Nasdaq: LVTX) has appointed Amy Garabedian as its new general counsel and corporate secretary. With over 15 years of experience in the life sciences sector, Garabedian previously served as associate general counsel at Spark Therapeutics. Her expertise in corporate and strategic legal matters is expected to bolster LAVA's clinical development efforts as it advances its bispecific gamma-delta T cell engagers for cancer treatment. LAVA plans to report Phase 1 clinical data in 2022, reinforcing its commitment to innovative cancer therapies.